Search results for "ONCOLOGIA"

showing 10 items of 386 documents

Corrigendum to “Liquid biopsies in lung cancer: The new ambrosia of researchers” [Biochem. Biophys. Act. 1846(2014) 539–546]

2015

a Phase I — Early Clinical Trials Unit, Oncology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium b Molecular Pathology Unit, Pathology Department, Antwerp University Hospital, Wilrijkstraat 10, Edegem 2650, Belgium c Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Via Liborio Giuffre 5, Palermo 90127, Italy d Department of Investigational Cancer Therapeutics (Phase I Program), The University of Texas MD Anderson Cancer Center, Holcombe Blvd 1400, Unit 455, Houston 77030, USA e Department of Biopathology and Medical and Forensic Biotechnologies, Section of Biology and Genetics, University of Palermo, V…

University campusCancer ResearchOncologyF-CenterSettore MED/06 - Oncologia MedicaGeneticsThe name of the author Daniele Santini was inadvertently omitted from the author line. The correct author line is above.Library scienceUniversity hospitalBiochimica et Biophysica Acta (BBA) - Reviews on Cancer
researchProduct

VEGF-targeted therapy stably modulates the glycolytic phenotype of tumor cells

2014

Abstract Anti-VEGF therapy perturbs tumor metabolism, severely impairing oxygen, glucose, and ATP levels. In this study, we investigated the effects of anti-VEGF therapy in multiple experimental tumor models that differ in their glycolytic phenotypes to gain insights into optimal modulation of the metabolic features of this therapy. Prolonged treatments induced vascular regression and necrosis in tumor xenograft models, with highly glycolytic tumors becoming treatment resistant more rapidly than poorly glycolytic tumors. By PET imaging, prolonged treatments yielded an increase in both hypoxic and proliferative regions of tumors. A selection for highly glycolytic cells was noted and this met…

Vascular Endothelial Growth Factor ACancer ResearchPathologymedicine.medical_specialtyNecrosismedicine.medical_treatmentAngiogenesis InhibitorsMice SCIDBiologySCIDAntibodies Monoclonal HumanizedAntibodiesCell LineTargeted therapyMiceRandom AllocationCell Line TumorNeoplasmsMonoclonalAngiogenesis Inhibitors; Animals; Antibodies Monoclonal Humanized; Bevacizumab; Cell Line Tumor; Female; Glycolysis; Humans; MCF-7 Cells; Mice; Mice Inbred BALB C; Mice SCID; Molecular Targeted Therapy; Neoplasms; Phenotype; Random Allocation; Vascular Endothelial Growth Factor A; Xenograft Model Antitumor AssaysmedicineAnimalsHumansGlycolysisMolecular Targeted Therapycancer-cellAnti-VEGF therapyHumanizedInbred BALB CMED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAMice Inbred BALB CTumorpositron emission tomography antiangiogenesis glucose metabolism hypoxiaXenograft Model Antitumor AssaysPhenotypeBlockadeBevacizumabVascular endothelial growth factor APhenotypeOncologyCell cultureMonoclonalMCF-7 CellsCancer researchMED/06 - ONCOLOGIA MEDICAFemalemedicine.symptomGlycolysis
researchProduct

Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules

2011

The treatment of solid malignancies includes various target drugs, such as monoclonal antibodies and tyrosine kinase inhibitors, which exert their effect alone or in combination with chemotherapy. The main part of these molecules have a target on proteins of EGFR and VEGF pathways. The particular toxicity profile and the financial impact, deriving from the application of these agents in cancer treatment, prompted a lot of researches to define predictive factors of their efficacy. Various biomarker were identified among the components of the targeted pathways. However just few studies allowed to identify specific factors to predict the toxicity of these drugs. In this review EGFR and VEGF-re…

Vascular Endothelial Growth Factor Amedicine.drug_classSettore MED/06 - Oncologia Medicamedicine.medical_treatmentClinical BiochemistryAngiogenesis InhibitorsAntineoplastic AgentsPharmacologyMonoclonal antibodyTargeted therapyAntineoplastic AgentNeoplasmsProtein-Tyrosine KinasemedicineHumansAngiogenesis Inhibitors; Antibodies Monoclonal; Antineoplastic Agents; Humans; Neoplasms; Protein-Tyrosine Kinases; Receptor Epidermal Growth Factor; Treatment Outcome; Vascular Endothelial Growth Factor ATarget therapyPharmacologyAnti vegfChemotherapybusiness.industryAntibodies MonoclonalProtein-Tyrosine KinasesErbB ReceptorsTreatment OutcomeToxicityCancer researchBiomarker (medicine)NeoplasmReceptor Epidermal Growth FactorbusinessTyrosine kinaseAngiogenesis InhibitorHuman
researchProduct

Oncogeriatry: Communication, sharing, coordination of an emerging reality. The IIIrd Official Meeting of the AIOM Working Group on Oncogeriatry

2010

The clinical management of the oncological elderly patient represents one of the most important challenges for today's oncology and, above all, for the future. The number of elderly patients with neoplastic pathologies is destined to increase proportionally to the duration of life and therefore a correct management of their conditions becomes an element of priority from the scientific and economic point of view. Close relationships and collaborations between Oncologist and Geriatrics are definitely desirable to be able to guarantee the best way for a good treatment (specific and of support) of these elderly patients. The components of the AIOM Working Group on Oncogeriatry have gathered the…

Working groupSettore MED/06 - Oncologia MedicaGuidelineOncogeriatry
researchProduct

Alteration of the YY1/RKIP ratio is a frequent event in hepatocellular carcinoma

2009

Yin Yang 1 Raf-1 kinase inhibitor protein Hepatocellular carcinoma ApoptosisSettore MED/12 - GastroenterologiaSettore MED/06 - Oncologia MedicaSettore BIO/14 - Farmacologia
researchProduct

“THERMAL NOCICEPTION STUDIES IN ZEBRAFISH”

2012

Background Nociception was defined by Sherrington as the mechanism used to sense painful events. Despite the value of current animal models for nociception and pain, we have not yet understood in full how these mechanisms operate. Aim Here we propose a novel approach using zebrafish (Danio rerio) larvae in order to determine if the fish is suitable for the study of pain stimuli. Taking advantage of the fact that, in response to noxious stimuli, the expression of several genes in mammals is induced in neurons of the spinal cord and the dorsal root ganglia (DRG), we investigated if such mechanism is evolutionary conserved in the Zebrafish. Materials and Methods We cloned homologues of mammals…

ZEBRAFISHSettore MED/06 - Oncologia MedicaNOCICEPTION
researchProduct

Effects of anti-miR-182 on Thrombospondin-1 expression in human colon cancer cells

2012

ABSTRACT Background: MicroRNAs are small non-coding RNAs that regulate the expression of different genes, involved in cancer progression, angiogenesis and metastasis. Bio-informatic statistical analysis indicated that miR-182, over-expressed in colorectal cancer (CRC), has like predictive target Thrombospondin-1 (TSP-1), a protein inversely correlated with tumor vascularity and metastasis that results downregulated in different types of cancer including CRC. Early Growth Response 1 (Erg-1) and Specificity Protein 1 (Sp-1) are transcriptional factors that bind consensus sequence on TSP-1 gene promoter and are putative target of miR-96/182/183 cluster. MiR-182 could target SMAD4, which expres…

anti-miR-182Settore MED/06 - Oncologia MedicaThrombospondin-1
researchProduct

Study on b-Catenins mechanisms of regulation in zebrafish blastula embryo

2012

Background: â-catenin is a central component of the cadherin cell adhesion complex but also it plays an essential role in the canonical-Wingless/Wnt signaling pathway. In vertebrates, one of the initial steps for the establishment of the correct dorso-ventral (D/V) pattern in the embryo is the cytoplasmic accumulation followed by nuclear localization of â-catenin in the cells of the prospective dorsal side of the embryo. In zebrafish there are two â-catenins, 92,7% identical. The mutant fish line Ichabod (ich), with a mutation in the region of the â-catenin2 promoter that causes a decrease in the maternal accumulation of â-catenin2 protein in the embryos, fail to nuclear localize â- catenin…

b-CateninSettore MED/06 - Oncologia Medicazebrafish blastula embryo
researchProduct

Bienestar emocional, imagen corporal, autoestima y sexualidad en mujeres con cáncer de mama

2013

Como toda enfermedad amenazante para la vida de las personas, el cáncer de mama supone una situación de estrés en las mujeres que lo padecen, tanto desde un punto de vista físico como psicológico, puesto que además de tener que enfrentarse a la enfermedad y sus tratamientos, las mujeres han de adaptarse a cambios referidos a su imagen corporal y a los sentimientos y actitudes que ello conlleva (Sebastián et al., 2007). El bienestar emocional de las pacientes con cáncer de mama por ende se ve afectado y tal como se refleja en numerosos estudios, las alteraciones más prevalentes son la ansiedad y la depresión (Barreto y Pintado, 2011; Bellver, 2007; Toledo, Ferrero y Barreto, 1994; Zhao et al…

bienestar emocional:PSICOLOGÍA [UNESCO]psicooncologiaUNESCO::PSICOLOGÍA
researchProduct

“Role of biomarkers in the regulatory process”

2007

biomarkersdrug developmentEMEASettore MED/06 - Oncologia Medica
researchProduct